MedTrace Logo

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

NCT00478725 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-11-17

No results posted yet for this study

Summary

To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

GW786034, oral

oral, 800 mg

DRUG

GW786034, IV

IV, 5 mg

DRUG

GW786034, radiolabeled oral

oral, 400 mg radiolabeled

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-18
Primary Completion
2008-07-01
Completion
2008-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00478725 on ClinicalTrials.gov